+44 (0)1865 595230
0 Items

Ebola

Ebola virus causes a viral hemorrhagic fever of humans and other primates. The disease has a high risk of death, killing between 25 and 90 percent of those infected, with an average of about 50 percent. Since a very large outbreak in West Africa in 2014/15, there have been further occasional outbreaks leading to continuing concern about the disease.

The Native Antigen Company offer a range of recombinant Ebola proteins and antibodies to support research into the disease.

Ebola background

Ebola virus disease (EVD) is a severe disease caused by several species of Ebolavirus (EBOV), in the family Filoviridae. Prior to 2007, four species of EBOV had been identified, with two (Zaire ebolavirus and Sudan ebolavirus) having caused significant disease outbreaks in humans. The presence of a fifth EBOV virus species, Bundibugyo ebolavirus (BEBOV) was identified after an outbreak of EVD in the Bundibugyo District of western Uganda in 2007. Outbreaks of EVD are associated with person-to-person transmission after the virus is introduced into humans from a zoonotic reservoir. During outbreaks the virus is commonly transmitted through direct contact with infected persons or their bodily fluids. The onset of EVD is associated with nonspecific clinical symptoms, including fever, myalgia, headache, abdominal pain, nausea, vomiting, and diarrhoea. In the later stages of disease, overt haemorrhage has been reported in up to 50% of cases.

The Zaire subtype of the EBOV family is currently the most important in relation to outbreaks of disease in humans. This subtype has been responsible for the largest ever outbreak of EVD, which started in West Africa in 2014, and was finally declared over only in early 2016.

Reference

Adam MacNeil et al (2010). Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda. Emerg Infect Dis. 16(12): 1969–1972.

Ebola Antigens

The Native Antigen Company supply highly purified viral antigens, developed using our proprietary mammalian expression system to support researchers working with EBOV including envelope glycoproteins from both Zaire and Bundibugyo strains, and also Ebola virus-like particles which contain nucleoprotein, glycoprotein and VP40 antigens.

 

Ebola Antibodies

To complement our range of Ebola virus antigens we are pleased to offer a range of monoclonal and polyclonal antibodies specific for Ebola virus proteins. These include antibodies that are specific for Ebola Nucleoprotein and VP 40 antigens.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

A silver-lining from Zika virus?

Zika virus (ZIKV) is an enveloped single stranded RNA virus. It is a member of the Flavivirus genus of the family Flaviviridae, which is transmitted to humans primarily through the bite of the Aedes aegypti mosquito. In 2015, a major outbreak of Zika virus was...

Congenital CMV – a problem ignored?

Congenital CMV infection – a serious problem that receives little attention Cytomegalovirus (CMV) is a human specific double stranded DNA virus, belonging to the Herpesviridae family. CMV is ubiquitous and CMV infection is globally widespread. The virus can be...

New Nipah Virus antigens now available from The Native Antigen Company

Infection with Nipah Virus (NiV) was first recognised in Malaysia 1998/1999, where a major outbreak occurred in pigs and humans. NiV infection is now endemic in South Asia and several outbreaks of NiV infection have been reported in India and Bangladesh. Currently an...

Get in Touch With Us

The Native Antigen Company sometimes likes to send exclusive information and offers to our customers, please let us know if you are happy to receive these

15 + 9 =

Customer Feedback